Intellia Therapeutics (NTLA) Total Liabilities (2022 - 2025)
Historic Total Liabilities for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $176.9 million.
- Intellia Therapeutics' Total Liabilities fell 1607.84% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year decrease of 1607.84%. This contributed to the annual value of $319.1 million for FY2024, which is 2721.24% up from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' Total Liabilities is $176.9 million, which was down 1607.84% from $183.6 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Total Liabilities ranged from a high of $319.1 million in Q4 2024 and a low of $171.0 million during Q1 2021
- Its 5-year average for Total Liabilities is $226.1 million, with a median of $223.5 million in 2024.
- Per our database at Business Quant, Intellia Therapeutics' Total Liabilities skyrocketed by 15527.74% in 2021 and then plummeted by 2064.38% in 2023.
- Over the past 5 years, Intellia Therapeutics' Total Liabilities (Quarter) stood at $254.2 million in 2021, then grew by 11.92% to $284.5 million in 2022, then dropped by 11.85% to $250.8 million in 2023, then grew by 27.21% to $319.1 million in 2024, then plummeted by 44.57% to $176.9 million in 2025.
- Its Total Liabilities stands at $176.9 million for Q3 2025, versus $183.6 million for Q2 2025 and $206.2 million for Q1 2025.